Current Studies / INVOKE AL002-2
Glasgow Memory Clinic is looking for volunteers who may be suitable to take part in the INVOKE AL002-2 Clinical Research Study.
The study medication (called AL002) could help reduce the build-up of proteins in the brain, which are associated with Alzheimer’s disease. It is given by intravenous (IV) infusion once every four weeks during the treatment phase of the study.
Participants will be randomly placed into one of four study treatment groups. Three groups
will receive a designated dose of the study medication and the other group will receive a placebo.
Participants will be in this study for up to about 28 months and visit Glasgow Memory Clinic up to about 32 times. This study has three periods:
- Screening (about eight to 11 weeks): a series of tests will be performed to see if you qualify for the study. If you agree to participate in optional assessments, you may have a screening period of up to 11 weeks.
- Study treatment (48 to 96 weeks): you will receive the study medication during this period.
- Follow-up (eight weeks): two visits to Glasgow Memory Clinic for final tests.
You or a loved one may be able to participate in the INVOKE AL002-2 study if you/they:
- Are between 50 and 85 years old
- Have been diagnosed with early Alzheimer’s disease
- Weigh between 45 and 120kg (between 7st 1lb and 18st 13lbs)
- Have no other cognitive condition other than Alzheimer’s
- Do not live in a long-term care or nursing home
- Have a study partner who knows you and is willing to attend appointments with you throughout the study
*The study partner must be able to speak about the participant’s day to day routines and any changes with the research staff throughout the study
Other eligibility criteria will apply.
If you are interested in participating or think a loved one may be interested, please take a short pre-screener below.